home / stock / atnm / atnm quote
Last: | $6.87 |
---|---|
Change Percent: | -0.3% |
Open: | $6.58 |
Close: | $6.87 |
High: | $6.92 |
Low: | $6.485 |
Volume: | 203,900 |
Last Trade Date Time: | 04/26/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$6.87 | $6.58 | $6.87 | $6.92 | $6.485 | 203,900 | 04-26-2024 |
$6.56 | $6.96 | $6.56 | $6.97 | $6.47 | 328,850 | 04-25-2024 |
$7.06 | $6.93 | $7.06 | $7.32 | $6.8809 | 153,433 | 04-24-2024 |
$6.96 | $7.03 | $6.96 | $7.43 | $6.85 | 185,256 | 04-23-2024 |
$7.17 | $6.92 | $7.17 | $7.34 | $6.82 | 192,609 | 04-22-2024 |
$6.85 | $6.64 | $6.85 | $7.01 | $6.6 | 347,635 | 04-19-2024 |
$6.67 | $7.26 | $6.67 | $7.5125 | $6.66 | 420,871 | 04-18-2024 |
$7.25 | $7.73 | $7.25 | $7.817 | $7.2 | 297,442 | 04-17-2024 |
$7.74 | $8.45 | $7.74 | $8.45 | $7.65 | 373,923 | 04-16-2024 |
$8.44 | $8.95 | $8.44 | $9.1 | $8.28 | 255,522 | 04-15-2024 |
$9 | $8.97 | $9 | $9.04 | $8.55 | 303,644 | 04-12-2024 |
$9.09 | $9.02 | $9.09 | $9.28 | $9 | 461,385 | 04-11-2024 |
$8.99 | $8.79 | $8.99 | $9.15 | $8.72 | 344,890 | 04-10-2024 |
$8.98 | $9.12 | $8.98 | $9.13 | $8.7 | 343,856 | 04-09-2024 |
$9.13 | $9.5 | $9.13 | $9.68 | $8.87 | 432,190 | 04-08-2024 |
$9.54 | $9.03 | $9.54 | $9.57 | $8.84 | 487,033 | 04-05-2024 |
$9.13 | $8.99 | $9.13 | $9.36 | $8.9578 | 392,522 | 04-04-2024 |
$8.84 | $8.53 | $8.84 | $9.22 | $8.53 | 402,353 | 04-03-2024 |
$8.6 | $8.37 | $8.6 | $8.78 | $8.3 | 287,889 | 04-02-2024 |
$8.56 | $7.83 | $8.56 | $8.74 | $7.7 | 627,381 | 04-01-2024 |
News, Short Squeeze, Breakout and More Instantly...
Actinium Pharmaceuticals Inc. Company Name:
ATNM Stock Symbol:
NYSE Market:
Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting PR Newswire -- Iomab-B led bone marrow t...
Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation at the 50th European Bone Marrow Transplant Annual Meeting PR Newswire -&...